What is it about?
Cancer-associated venous thromboembolism (VTE) is common in patients with primary lung cancer.It has been understudied which authoritative risk assessment score of cancer-associated VTE is optimal for the assessment of VTE development in hospitalized medical patients with lung cancer.Patients with lung cancer who had undergone computed tomography pulmonary angiography (CTPA),compression ultrasonography (CUS) of lower and upper extremities, and/or planar ventilation/perfusion (V/Q) scan to confirm the presence or absence of VTE during a medical hospitalization were retrospectively reviewed. Based on the actual prevalence of VTE among all patients, the possibility of VTE were reassessed with the Khorana score, the PROTECHT score, the CONKO score, the ONKOTEV score, the COMPASS-CAT score, and the CATS/MICA score, to compare their assessment accuracy for VTE development.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This finding could be conducive to the assessment of VTE development and thromboprophylaxis for hospitalized medical patients with lung cancer. Prospective validation of the present conclusions is warranted in the future.
Perspectives
Among the Khorana score, the PROTECHT score, the CONKO score, the ONKOTEV score, the COMPASSCAT score, and the CATS/MICA score which are approved by authoritative guidelines, the ONKOTEV score is optimal for the assessment of VTE development in hospitalized medical patients with lung cancer.
Dr Wei Xiong
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Read the Original
This page is a summary of: Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer, Thrombosis Journal, December 2021, Springer Science + Business Media,
DOI: 10.1186/s12959-021-00339-x.
You can read the full text:
Contributors
The following have contributed to this page
